Amar U Kishan, Audrey Dang, Alan J Katz, Constantine A Mantz, Sean P Collins, Nima Aghdam, Fang-I Chu, Irving D Kaplan, Limor Appelbaum, Donald B Fuller, Robert M Meier, D Andrew Loblaw, Patrick Cheung, Huong T Pham, Narek Shaverdian, Naomi Jiang, Ye Yuan, Hilary Bagshaw, Nicolas Prionas, Mark K Buyyounouski, Daniel E Spratt, Patrick W Linson, Robert L Hong, Nicholas G Nickols, Michael L Steinberg, Patrick A Kupelian, Christopher R King
Importance: Stereotactic body radiotherapy harnesses improvements in technology to allow the completion of a course of external beam radiotherapy treatment for prostate cancer in the span of 4 to 5 treatment sessions. Although mounting short-term data support this approach, long-term outcomes have been sparsely reported. Objective: To assess long-term outcomes after stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. Design, Setting, and Participants: This cohort study analyzed individual patient data from 2142 men enrolled in 10 single-institution phase 2 trials and 2 multi-institutional phase 2 trials of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer between January 1, 2000, and December 31, 2012...
February 1, 2019: JAMA network open